Elevated Capital Advisors LLC Sells 13,424 Shares of Merck & Co., Inc. $MRK

Elevated Capital Advisors LLC reduced its position in Merck & Co., Inc. (NYSE:MRK) by 84.6% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,440 shares of the company’s stock after selling 13,424 shares during the quarter. Elevated Capital Advisors LLC’s holdings in Merck & Co., Inc. were worth $293,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the 4th quarter worth approximately $26,000. United Financial Planning Group LLC purchased a new position in Merck & Co., Inc. during the 3rd quarter valued at $31,000. Finally, High Note Wealth LLC boosted its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after acquiring an additional 109 shares during the period. Institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Down 1.1%

MRK opened at $123.72 on Friday. The company has a quick ratio of 1.06, a current ratio of 1.30 and a debt-to-equity ratio of 1.02. The stock’s fifty day moving average is $118.83 and its two-hundred day moving average is $116.28. The company has a market capitalization of $305.56 billion, a P/E ratio of 34.85, a PEG ratio of 2.68 and a beta of 0.19. Merck & Co., Inc. has a 52 week low of $76.66 and a 52 week high of $130.29.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share for the quarter, topping the consensus estimate of ($1.47) by $0.19. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. During the same period in the prior year, the business earned $2.22 EPS. The business’s revenue for the quarter was up 4.9% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.040-5.160 EPS. Analysts forecast that Merck & Co., Inc. will post 5.17 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, July 8th. Investors of record on Monday, June 15th were paid a $0.85 dividend. The ex-dividend date of this dividend was Monday, June 15th. This represents a $3.40 dividend on an annualized basis and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research report on Friday, May 15th. Scotiabank lifted their target price on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, June 30th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $120.00 price target on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Bank of America lifted their price objective on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Finally, Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 price objective on shares of Merck & Co., Inc. in a research report on Wednesday. One analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and an average target price of $132.72.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The FDA approved KEYTRUDA and KEYTRUDA QLEX, each combined with Padcev, for use before and after surgery in adults with muscle-invasive bladder cancer. This expands Merck’s flagship oncology franchise and could add to future revenue. Article Title
• Positive Sentiment: Analyst sentiment remains constructive, with Morgan Stanley slightly raising its price target and RBC Capital reiterating a Buy rating. That suggests Wall Street still sees upside despite the stock’s recent run. Article Title
• Positive Sentiment: Merck continues to attract investor attention thanks to strong year-to-date performance, a solid dividend yield, and a long record of dividend growth, which may support demand for the shares. Article Title
• Neutral Sentiment: Recent coverage also notes Merck is one of the more widely watched healthcare names on Zacks, but these mentions do not appear to add any new fundamental catalyst on their own. Article Title
• Negative Sentiment: Despite the upbeat news flow, the shares also face ongoing valuation and post-KEYTRUDA exclusivity concerns, which may limit upside if investors focus on Merck’s long-term patent risk. Article Title

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.